RatioTX
PrivateLast Round
Series B
Jan 17, 2024
Total Funding Raised
$90M
Company Overview
Ratio Therapeutics is a pharmaceutical company focused on accelerating the development of next-generation precision radiopharmaceuticals for solid tumors through its integrated proprietary R&D platforms that enhance the discovery and advancement of novel treatments with superior delivery, safety, and efficacy.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RatioTX Comps
Public and private peers based on sector, stage, and business model.
RatioTX Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 17, 2024 | ||||
| Series A Extension | Feb 1, 2023 | ||||
| Seed | Jun 10, 2022 |
RatioTX Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Center for Technology Licensing at Cornell University | Series B |
| Duquesne Family Office | Series A Extension |
| Charles and Lynn Schusterman Family Philanthropies | Series A Extension |
| Schusterman Family Investments | Series A Extension, Series B |
| Catalio Capital Management | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2026
Colin Hayward appointed as the new Chief Medical Officer.
- Jun 13, 2025
Partnered with Macrocyclics for radiopharmaceutical chelator platform.
RatioTX Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about RatioTX's valuation, stock price, and market status.
